Clinical Trials Logo

Neonatal Opioid Withdrawal clinical trials

View clinical trials related to Neonatal Opioid Withdrawal.

Filter by:
  • None
  • Page 1

NCT ID: NCT05746507 Recruiting - Sleep Disorder Clinical Trials

Night Respite for Postpartum Mothers With SUD

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

This single arm pilot feasibility study will evaluate the implementation of overnight infant respite care and parenting skills to mothers with substance use disorders in the early postpartum period residing in residential substance use disorder treatment programs.

NCT ID: NCT04298853 Completed - Clinical trials for Neonatal Abstinence Syndrome

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

Start date: June 30, 2020
Phase: Phase 4
Study type: Interventional

Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.

NCT ID: NCT01958476 Completed - Clinical trials for Neonatal Abstinence Syndrome

Improving Outcomes in Neonatal Abstinence Syndrome

Start date: September 2013
Phase: Phase 3
Study type: Interventional

1: SPECIFIC Aim I: To compare treatment options for neonatal abstinence syndrome (NAS) due to in-utero narcotic exposure. One hundred eighty four full-term infants with a diagnosis of NAS requiring medications will be studied. Infants will be randomized to receive either morphine or methadone. It is hypothesized that morphine treated infants will do better and require fewer days in the hospital compared to methadone treated infants. 2. SPECIFIC Aim II: To evaluate the effects of NAS treatment on long-term neurodevelopmental outcome. Infants will be evaluated with development testing at 18 months of age. It is hypothesized that morphine treated infants will have better neurodevelopmental outcomes. It is also hypothesized that neurobehavioral abnormalities identified at two weeks of age will correlate with neurodevelopmental impairment at 18 months. 3: SPECIFIC Aim III: To determine if common genetic variations in the genes involving narcotic action contribute to the severity of NAS. A DNA sample will be obtained from all infants and analyzed for differences in 3 key genes. This will then be correlated with short-term and long-term outcomes.